---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-038429"
form_type: "8-K"
ticker: "SABS"
cik: "0001833214"
company_name: "SAB Biotherapeutics, Inc."
filed_at: "2024-03-29T23:59:59+00:00"
generated_at: "2026-06-04T05:31:09.919599+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# SAB Biotherapeutics reports FY2023 net loss $42.2M; cash $56.6M; funding into 2026

## Summary
- Net loss $42.2M for FY2023 versus $18.7M in 2022; cash and equivalents $56.6M as of Dec 31, 2023.
- Completed equity financing up to $110M; expects cash with Tranche B warrant exercise to fund operations into 2026.
- Phase 1 trial of SAB-142 for Type 1 diabetes on track for data by end of 2024.
- Appointed Michael G. King Jr. as CFO; Andrew Moin and Katie Ellias added to board.
- R&D expenses $16.5M (down from $36.4M); G&A $23.8M (up from $16.4M).

## SEC filing metadata
- accession: 0000950170-24-038429
- form_type: 8-K
- ticker: SABS
- cik: 0001833214
- company_name: SAB Biotherapeutics, Inc.
- filed_at: 2024-03-29T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1833214/000095017024038429/0000950170-24-038429-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1833214/000095017024038429/sabs-20240329.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-038429
- JSON: https://secwatch.observer/filing/0000950170-24-038429.json
- Plain text: https://secwatch.observer/filing/0000950170-24-038429.txt

## Key facts
- Earnings Releases
  SAB Biotherapeutics, Inc. reported the year and quarter ended December 31, 2023 results: net income net loss of $42.2 million.
  - Period: the year and quarter ended December 31, 2023
  - Net income: net loss of $42.2 million
  - Result: reported results
  source text: SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results
  evidence_url: https://www.sec.gov/Archives/edgar/data/1833214/000095017024038429/0000950170-24-038429-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.